Dividend investors on the hunt for above average income opportunities may want to place a heavy emphasis on pharmaceutical stocks next year. Despite the political turmoil surrounding the Affordable Care Act (aka Obamacare), the pharmaceutical industry is still growing at a healthy clip, thanks primarily to the introduction of several game-changing new therapies for cancer and rare diseases over the past few years.
Within the realm of Big Pharma, for instance, AstraZeneca (NYSE:AZN), Pfizer (NYSE:PFE), and Sanofi (NYSE:SNY) all offer juicy dividend yields that exceed 3% at the moment, as well as broadly positive outlooks from both a near -- and long-term perspective. Armed with this insight, let's consider why these three pharmaceutical giants may be worth owning in 2018, and beyond.
Source: Motley Fool
Related Articles:
- 7 Stocks With A Vision Of Higher Dividends
- 6 Higher-Yielding Consumer Stocks With A History of Rising Dividends
- Are Defense Stocks Good Defensive Stocks?
- 10 Stocks That Have Paid Uninterrupted Dividends Since 1895
- Who is David Dodd and Why Should We Listen to Him
________________________________________________________________
Subscribe to:
Post Comments (Atom)
Popular Posts Last 30 Days
-
These days, the healthcare stocks are looking pretty healthy compared to stocks in other spaces. Despite political pressures about lowering ...
-
Nothing makes life easier for an investor than finding the kind of stocks where you can park money for a long, long time, trusting that they...
-
These three dividend aristocrats have beaten the market during the three most recent pullbacks. They've also outperformed in 2019. There...
-
As the sun sinks on another summer and Labor Day taunts with the pitiful proposition of just 24 hours less work, it stands to reason that so...
-
In Five High-Dividend Stocks You Should Watch, we discussed five dividend stocks, including MLPs, trading at yields above 11%. In this artic...
-
The past decade has rewarded investors with remarkable returns, but investors might not want to underestimate the odds that an economic rece...
-
This company recently released solid second quarter earnings. The mortgage REIT once again outearned its dividend with core earnings in Q2-2...
-
This company released Q2-2019 results recently. The results beat both revenue and earnings estimates. It reported decreasing earnings on the...
-
Conservative investors should adopt the same precautions toward monthly dividend stocks as you would any income-generating investment. For i...
-
As a risk-averse income investor, I always approach double-digit yielders with caution. The reason is simple: when most blue-chip companies ...
0 comments
Post a Comment
Post a Comment
Note: Only a member of this blog may post a comment.